Pharmaceutical compositions

Details Pharmaceutical compositions Pharmaceutical compositions

2005-09-27

2005-09-27

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C424S400000, C424S439000, C424S450000, C514S183000, C514S277000, C514S279000, C514S299000, C514S311000, C514S315000, C514S317000, C514S319000, C514S320000, C514S323000, C514S329000, C514S330000

Reexamination Certificate

active

06949257

ABSTRACT:
Spontaneously dispersible pharmaceutical compositions comprising a piperidine, e.g. 1-acylpiperidine Substance P Antagonist and its use in the treatment of CNS disorders, e.g. depression and social phobia, and respiratory diseases, e.g. asthma and chronic bronchitis.

REFERENCES:
patent: 5310743 (1994-05-01), Schilling et al.
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5646144 (1997-07-01), Schilling et al.
patent: 5730998 (1998-03-01), De Lacharriere et al.
patent: 5744156 (1998-04-01), De Lacharriere et al.
patent: 5886011 (1999-03-01), Tanoue et al.
patent: 5952004 (1999-09-01), Rudnic et al.
patent: 5965562 (1999-10-01), Ofner et al.
patent: 120 262 (1984-10-01), None
patent: 707 006 (1996-04-01), None
patent: 2270842 (1994-03-01), None
patent: 2278780 (1994-12-01), None
patent: 2308545 (1997-07-01), None
patent: WO 94/00123 (1994-01-01), None
patent: WO 97/22358 (1997-06-01), None
patent: WO 97/25977 (1997-07-01), None
patent: WO 97/45119 (1997-12-01), None
patent: WO 99/61025 (1999-12-01), None
Linder, Derwent Abstracts, 1994-008363 [02], (WO 94/00123-Jan. 6, 1994).
Fries, Derwent Abstracts, 1984-214059 [35], (EP 120 262-Jul. 13, 1988).
Skagerlind et al., “Surfactant Interference on Lipase Catalysed Reactions in Microemulsions”, J. Chem. Technol. Biotechnol., vol. 54, No. 3, pp. 277-282 (1992).
Wells et al., “Effect of Surfactants on Release of a Highly Water-Soluble Medicinal Compund from an Inert, Heterogeneous Matrix”, J. Pharm. Sci., vol. 81, No. 5, pp. 453-457 (1992).
Drewe et al., “Enhancement of the Oral Absortion of Cyclosporin in Man”, Br. J. Clin. Pharmacol., vol. 34, No. 1, pp. 60-64 (1992).
Aungst, “Novel Formulation Strategies for Improving Oral Bioavailability of Drugs with Poor Membrane Permeation or Presystemic Metabolism”, J. Pharm. Sci., vol. 82, No. 10, pp. 979-987 (1993).
Kondo et al., “Improved Oral Absorption of Entreric Coprecipitates of a Poorly Soluble Drug”, J. Pharm. Sci., vol. 83, No. 4, pp. 566-570 (1994).
Constantinides et al., “Formulation and Intestinal Absorption Enhancement Evaluation of Water-In-Oil Microelmulsions Incorporating Medium-Chain Glycerides”, Pharm. Res., vol. 11, No. 10, pp. 1385-1390 (1994).
Constantinides, “Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects”, vol. 12, No. 11, pp. 1561-1572 (1995).
Ho et al., “Preparation of Microemulsions Using Polyglycerol Fatty Acid Esters as Surfactant for the Delivery of Protein Drugs”, J. Pharm. Sci., vol. 85, No. 2, pp. 138-143 (1996).
Avramiotis et al., “Structural and Dynamic Properties of Lecithin-Alcohol Based w/o Microemulsions: A Luminescence Quenching Study”, J. Colloid Interface Sci., vol. 194, No. 2, pp. 326-331 (1997).
Aramaki et al., “Effect of Temperature on the Phase Behavior of Ionic-Nonionic Microemulsions”, J. Colloid Interface Sci., vol. 196, No. 1, pp. 74-78 (1997).
Gonsalves et al., “Synthesis and Surface Characterization of Functionalized Polylactide Copolymer Microparticles”, Biomaterials, vol. 19, No. 16, pp. 1501-1505 (1998).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3421054